Coming of Age:Anti–Cytokine Therapies

Table 1.

Development of anti-cytokine therapeutics

Drug Targeted cytokine Biologic type Indication Clinical status Company
Cancer
    BE-8 IL-6 Murine mAb B-lympho proliferative disorder; Multiple myeloma Phase I Diaclone
    AvastinTM (bevacizumab) Vascular endothelial growth factor Humanized mAb Advanced breast and colorectal cancer Phase III Genentech
Autoimmune Disorder
    REMICADE® (infliximab) TNF-α Chimeric mAb RA, CD; Psoriasis Approved;Phase II/III Johnson & Johnson/Centocor
    Enbrel® (etanercept) TNF-α, LT-α Receptor/Ig fusion protein RA, JRA, Psoriatic arthritis;Psoriasis Approved; Immunex
    D2E7 (adalimumab) TNF-α Human mAb RA Phase III Abbott
    HuMax-IL15 IL-15 Human mAb RA Phase I/II Genmab A/S, Immunex
    ABX-IL-8 IL-8 Human mAb Psoriasis Phase II Abgenix
    KineretTM (anakinra) IL-1 receptor Receptor antagonist RA Approved Amgen
Transplantation
    Simulect® (basiliximab) IL-2Rα Chimeric mAb Acute kidney transplant rejection Approved Novartis
    Zenapax® (daclizimab) IL-2Rα Humanized mAb Acute kidney transplant rejection Approved Protein Design Labs/Hoffman LaRoche
Respiratory
NuvanceTM (altrakincept) IL-4 Receptor/Ig fusion protein Asthma Phase II Immunex
SB240683 IL-4 Humanized mAb Asthma Phase II Protein Design Labs/GSK
SB240563 (mepolizumab) IL-5 Humanized mAb Asthma Phase II GSK
ABX-IL-8 IL-8 Human mAb Chronic obstructive pulmonary disease Phase II Abgenix

This Article

  1. MI February 2002 vol. 2 no. 1 36-46